Biotech Active Runners: Ariad Pharmaceuticals (NASDAQ:ARIA), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Novavax (NASDAQ:NVAX)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Net loss for the fourth quarter ended December 31, 2013 was $74.2 million, or $0.40 per share, compared to a net loss of $60.5 million, or $0.36 per share, for the same period in 2012. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock … Continue reading Biotech Active Runners: Ariad Pharmaceuticals (NASDAQ:ARIA), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Novavax (NASDAQ:NVAX)

Biotech Losers: Novavax (NASDAQ:NVAX), Achillion Pharmaceuticals (NASDAQ:ACHN), The Clorox (NYSE:CLX), Halozyme Therapeutics (NASDAQ:HALO)

Novavax, Inc. (NASDAQ:NVAX) is a vaccine company that is likely to have multiple milestones this year. It has U.S. government funding for seasonal and pandemic flu, and is developing its own products for respiratory syncytial virus (RSV). Novavax, Inc. (NASDAQ:NVAX) stock performance was -5.02% in last session and finished the day at $6.05. Traded volume was 4.36million shares in the last session and the average … Continue reading Biotech Losers: Novavax (NASDAQ:NVAX), Achillion Pharmaceuticals (NASDAQ:ACHN), The Clorox (NYSE:CLX), Halozyme Therapeutics (NASDAQ:HALO)

Novavax, Inc. (NASDAQ:NVAX) announced that it will host a conference call and webcast to report its fourth quarter and year-end 2013 financial results on Monday, March 10, 2014, at 4:30 p.m. ET. Novavax, Inc. (NASDAQ:NVAX) dropped -5.02 percent to $6.05 yesterday on volume of 4.36 million shares. The intra-day range of the stock was $5.86 to $6.47. Novavax, Inc. (NASDAQ:NVAX) has a market capitalization of … Continue reading NASDAQ Losers: Plug Power Inc (NASDAQ:PLUG), Novavax (NASDAQ:NVAX), FireEye Inc (NASDAQ:FEYE), Children’s Place Retail Stores (NASDAQ:PLCE)

Pfizer Inc. (NYSE:PFE) has begun testing an over-the-counter version of Lipitor, the blockbuster drug that has plumped up the pharmaceutical giant’s coffers for more than a decade. Pfizer Inc. (NYSE:PFE) stock performance was 2.22% in last session and finished the day at $32.69. Traded volume was 26,325,091 million shares in the last session and the average volume of the stock remained 26.27 million shares. The … Continue reading Healthcare Sector Most Active: Pfizer Inc. (NYSE:PFE), Novavax (NASDAQ:NVAX), Boston Scientific Corporation (NYSE:BSX), Dendreon Corporation (NASDAQ:DNDN)

Novavax, Inc. (NASDAQ:NVAX), announced on Thursday that the Biomedical Advanced Research and Development authority extended the base period of performance of a contract with the pharmaceutical company for its recombinant seasonal and pandemic influenza vaccines. Novavax, Inc. (NASDAQ:NVAX) stock performance was 1.27% in last session and finished the day at $6.38. Traded volume was 13,436,282 million shares in the last session and the average volume … Continue reading Biotech Active Runners: Novavax (NASDAQ:NVAX), VIVUS (NASDAQ:VVUS), Rexahn Pharmaceuticals (NYSEMKT:RNN), Ariad Pharmaceuticals (NASDAQ:ARIA)

Topeka Capital Markets restated their buy rating on shares of Discovery Communications (NASDAQ:DISCA) in a research note issued to investors on Monday. Discovery Communications, Inc. (NASDAQ:DISCA) belongs to Services sector. Its net profit margin is 23.00% and weekly performance is -2.66%. On last trading day company shares ended up $33.97. Discovery Communications, Inc. (NASDAQ:DISCA) distance from 50-day simple moving average (SMA50) is -3.03%. Novavax, Inc. … Continue reading Investors Should Watch: Discovery Communications, Inc. (NASDAQ:DISCA), Novavax, Inc. (NASDAQ:NVAX), Alibaba Group Holding Ltd (NYSE:BABA), Celgene Corporation (NASDAQ:CELG), GigaMedia Ltd. (NASDAQ:GIGM)